Global Long-acting PrEP Market Strategic Research Report

Scope of the Report

The global Long-acting PrEP market size is predicted to grow from US$ 305 million in 2025 to US$ 834 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.

Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop–start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers, elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services.In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.

The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery—reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.

Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations—risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother “start–pause–restart” pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.

Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug “tail,” injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity—aseptic manufacturing, cold-chain logistics, and reliable component availability—adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-acting PrEP market?

What factors are driving Long-acting PrEP market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-acting PrEP market opportunities vary by end market size?

How does Long-acting PrEP break out by Type, by Application?

This report presents a comprehensive overview of the global Long-acting PrEP market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Cabotegravir
• Lenacapavir
• Other

Segment by Dosing Interval

• Short-interval Injections
• Monthly Injections
• Quarterly Injections

Segment by Drug Properties

• Original Drug
• Generic Drug

Segment by Application

• Hospital
• Clinic
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Long-acting PrEP market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact